These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35372665)

  • 1. Clinical features and outcomes of patients in different age groups with non-valvular atrial fibrillation receiving oral anticoagulants.
    O UF; Chong TK; Wei Y; Paudel B; Giudici MC; Wong CW; Lei WK; Chen J; Wu W; Liu K
    Int J Cardiol Heart Vasc; 2022 Jun; 40():101009. PubMed ID: 35372665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study.
    Olsen AS; McGettigan P; Gerds TA; Fosbøl EL; Olesen JB; Sindet-Pedersen C; Staerk L; Lock Hansen M; Pallisgaard JL; Køber L; Torp-Pedersen C; Gislason GH; Lamberts M
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):292-300. PubMed ID: 31742339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany - A retrospective cohort study.
    Bonnemeier H; Huelsebeck M; Kloss S
    Int J Cardiol Heart Vasc; 2019 Jun; 23():100367. PubMed ID: 31111087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk.
    Godino C; Melillo F; Bellini B; Mazzucca M; Pivato CA; Rubino F; Figini F; Mazzone P; Della Bella P; Margonato A; Colombo A; Montorfano M
    EuroIntervention; 2020 Apr; 15(17):1548-1554. PubMed ID: 31845892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.
    Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Gastrointestinal Bleeding.
    Kwon S; Lee SR; Choi EK; Lee E; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
    Stroke; 2021 Jan; 52(2):511-520. PubMed ID: 33412904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
    Lip GYH; Keshishian AV; Zhang Y; Kang A; Dhamane AD; Luo X; Klem C; Ferri M; Jiang J; Yuce H; Deitelzweig S
    JAMA Netw Open; 2021 Aug; 4(8):e2120064. PubMed ID: 34398204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study.
    Loo SY; Coulombe J; Dell'Aniello S; Brophy JM; Suissa S; Renoux C
    BMJ Open; 2018 Jan; 8(1):e019638. PubMed ID: 29371284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study.
    Xiang W; Zhang J; Liu M; Liu F; Feng X; Wang Y
    Clin Interv Aging; 2015; 10():515-9. PubMed ID: 25767378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
    Tepper PG; Mardekian J; Masseria C; Phatak H; Kamble S; Abdulsattar Y; Petkun W; Lip GYH
    PLoS One; 2018; 13(11):e0205989. PubMed ID: 30383768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study.
    Krittayaphong R; Winijkul A; Methavigul K; Wongtheptien W; Wongvipaporn C; Wisaratapong T; Kunjara-Na-Ayudhya R; Boonyaratvej S; Komoltri C; Kaewcomdee P; Yindeengam A; Sritara P;
    BMC Cardiovasc Disord; 2018 Aug; 18(1):174. PubMed ID: 30144802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
    Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
    Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.
    Patti G; Pecen L; Lucerna M; Huber K; Rohla M; Renda G; Siller-Matula J; Ricci F; Kirchhof P; De Caterina R
    Am J Med; 2019 Jun; 132(6):749-757.e5. PubMed ID: 30664837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences.
    Waranugraha Y; Rizal A; Syaban MFR; Faratisha IFD; Erwan NE; Yunita KC
    Egypt Heart J; 2021 Aug; 73(1):70. PubMed ID: 34379219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmaco-utilization and outcomes in patients treated with oral anticoagulants from 2014 to 2015: evidences from administrative databases of the Romagna Local Health Unit].
    Degli Esposti L; Perrone V; Saragoni S; Buda S; Piovaccari G
    G Ital Cardiol (Rome); 2020 Jan; 21(1):25-33. PubMed ID: 31960832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.